Pam Cheng - Astrazeneca PLC President

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>AP</div>
AZN -- USA Stock  

Report: 30th of July 2020  

  President
Ms. Pam P. Cheng is Executive Vice President Operations and Information Technology of the Company. She joined AstraZeneca in June 2015 after having spent 18 years with MerckMSD in Global Manufacturing and Supply Chain and Commercial roles. Pam was the Head of Global Supply Chain Management Logistics for Merck from 2006 to 2011 and led the transformation of Merck supply chains across the global supply network. More recently, Pam was President of MSD China, responsible for MSDs entire business in China. Prior to joining Merck, Pam held various engineering and project management positions at Universal Oil Products, Union Carbide Corporationrationration and GAF Chemicals. Pam holds Bachelors and Masters degrees in chemical engineering from Stevens Institute of Technology in New Jersey and an MBA in marketing from Pace University in New York. In addition to her role at AstraZeneca, Pam serves as a nonexecutive Director of the Codexis Inc. Board . Pam also serves as an Advisor to the International Society of Pharmaceutical Engineering Board of Directors.
Age: 48  President Since 2015  MBA    
(44) 1223 352 858  www.astrazeneca.com

Pam Cheng Latest Insider Activity

Astrazeneca PLC Management Efficiency

Astrazeneca PLC has Return on Asset of 3.6 % which means that on every $100 spent on asset it made $3.6 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 11.66 %, implying that it generated $11.66 on every 100 dollars invested. Astrazeneca PLC management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Return on Investment is projected to rise to 9.64 this year. Return on Average Assets is projected to rise to 0.0205 this yearAstrazeneca PLC Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at about 0.41. Return on Average Assets is projected to rise to 0.0205 this year, although the value of Tax Assets will most likely fall to about 2.6 B. Astrazeneca PLC Total Liabilities is quite stable at the moment as compared to the past year. The company's current value of Total Liabilities is estimated at about 46.98 Billion. Current Liabilities is projected to rise to about 18.9 B this year, although the value of Liabilities Non Current will most likely fall to about 28.1 B.
The company has 20.98 B in debt with debt to equity (D/E) ratio of 1.72, which is OK given its current industry classification. Astrazeneca PLC has a current ratio of 0.74, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Katie WatsonGilead Sciences
N/A
Lafmin MorganGrifols S A
N/A
Abbas HussainGlaxoSmithKline PLC
2014
Paul BiondiBristol Myers Squibb
2018
Roger ConnorGlaxoSmithKline PLC
2018
Willie DeeseMerck Company
N/A
Hal BarronGlaxoSmithKline PLC
2018
Bill LouvGlaxoSmithKline PLC
2013
Murdo GordonBristol Myers Squibb
2016
Melissa BarnesEli Lilly And
2013
Paul AutenriedBristol Myers Squibb
2016
James FordGlaxoSmithKline PLC
2018
Kathryn WengelJohnson Johnson
2018
Carsten SchroederGrifols S A
N/A
Myles ONeillEli Lilly And
2018
Francis CussBristol Myers Squibb
2013
Joshua SmileyEli Lilly And
2018
Johna NortonEli Lilly And
2017
Phil ThomsonGlaxoSmithKline PLC
2017
Julie GerberdingMerck Company
2016
Anne WhiteEli Lilly And
2018

Company Summary

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca PLC operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 70600 people.Astrazeneca PLC (AZN) is traded on BATS Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom and employs 70,600 people. Astrazeneca PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

Astrazeneca PLC Leadership Team

Marc Dunoyer, Chief Financial Officer, Executive Director
Sherilyn McCoy, Non-Executive Independent Director
Genevieve Berger, Non-Executive Independent Director
Luke Miels, Executive Vice-President GPPS
Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines Development
Paul Hudson, Executive Vice President North America
Nazneen Rahman, Non-Executive Independent Director
Jose Baselga, Executive Vice President - Research & Development Oncology
JeanPhilippe Courtois, Non-Executive Independent Director
Thomas Larsen, IR Contact Officer
Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer
Tony Mok, Non-Executive Independent Director
Mark Mallon, Executive Vice President International
Fiona Cicconi, Executive Vice President - Human Resources
Deborah DiSanzo, Non-Executive Independent Director
Shriti Vadera, Non-Executive Independent Director
Leif Johansson, Non-Executive Independent Chairman of the Board
Leon Wang, Executive Vice President - International and China President
Ann Cairns, Non-Executive Director
Adrian Kemp, Company Secretary
Cornelia Bargmann, Non-Executive Director
Tim JacksonSmith, Non-Executive Director
Michel Demare, Non-Executive Independent Director
Graham Chipchase, Senior Non-Executive Independent Director
David Smith, Executive VP of Operations and Information Services
Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee
Pam Cheng, Executive Vice-President of Operations and Information Technology
Baroness Vadera, Non-Executive Independent Director
Philip Broadley, Non-Executive Independent Director
Narayan Seshadri, Independent Director
Jeffrey Pott, General Counsel
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business
David Fredrickson, Executive Vice-President Global Head Oncology Business Unit
Bahija Jallal, Executive Vice President MedImmune
Rudolph Markham, Non-Executive Independent Director
Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals
Weiying Wang, Non-Executive Director
Bruce Burlington, Non-Executive Independent Director
Marcus Wallenberg, Non-Executive Director
Iskra Reic, Executive Vice President - Europe and Canada

Stock Performance Indicators

Did you try this?

Run Portfolio Backtesting Now

   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module

Astrazeneca PLC Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Astrazeneca PLC and Gilead Sciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page